Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is ...

MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come ...

FDA announced the Rare Disease Framework Initiative, a new effort to reimagine how drugs and biologics for rare diseases are developed and reviewed. The initiative was outlined in ...

Vir Biotechnology, entered a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN dual-masked T-cell engager development candidates target ...

In today’s Pharmaceutical Executive Daily, Gilead and Vir Biotechnology enter a collaboration worth up to $1.87 billion to ...

Since prediction market platforms such as Kalshi began offering trade markets on regulatory reviews and clinical trial ...

Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years. Fox Rothschild's Mark Wagner on why the ...

Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and ...

PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that. Pharmaceutical Executive spoke with Mark Talens, CCO of PAXAFE at ...

Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics ...

Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona ...

Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s ...